Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01527838 | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | PHASE1 | COMPLETED | 10 | — | — | Jan 1, 2012 | Nov 1, 2013 | Sep 12, 2016 | 3 | United States |
To determine the minimally effective TNC dose for a single FT1050-treated CB unit based on neutrophil engraftment/chimerism when used for hematopoietic reconstitution following a reduced-intensity conditioning regimen for hematologic malignancies.
| Arm | Type | Description |
|---|---|---|
| Single FT1050 treated UCB Unit | EXPERIMENTAL | Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood |
| Name | Type | Description |
|---|---|---|
| Single FT1050 treated UCB unit | BIOLOGICAL | Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood |
Inclusion Criteria: 1. Subjects with hematologic malignancies for whom allogeneic stem cell transplantation is deemed clinically appropriate. Eligible diseases and stages include: * Non-Hodgkin's lymphoma or Hodgkin's lymphoma * Chronic lymphocytic leukemia (CLL) * Acute myelogenous leuke...